Table 2.
Genomic alterations associated with PFS in patients who received CDK4/6i as 1st- or 2nd-line therapy (N = 109): 17 genes were significantly associated with impaired PFS in the Cox proportional hazard model with p-value ≤ 0.15 and HR ≥ 1.5 or HR ≤ 0.5.
| Patients (n) | HR | p-Value | 95% CI | FDR | |
|---|---|---|---|---|---|
| MLL3 mut | 4 | 4.01 | 0.01 | 1.42–11.28 | 0.32 |
| ZNF703 amp | 8 | 2.55 | 0.01 | 1.21–5.378 | 0.32 |
| FGFR1 amp | 23 | 1.78 | 0.02 | 1.09–2.90 | 0.32 |
| CDKN2B loss | 4 | 3.27 | 0.02 | 1.18–9.11 | 0.32 |
| GPR124 mut | 2 | 5.34 | 0.02 | 1.25–22.86 | 0.32 |
| CDK4 amp | 5 | 2.75 | 0.03 | 1.09–6.93 | 0.36 |
| PALB2 mut | 4 | 2.83 | 0.05 | 1.01–7.90 | 0.40 |
| MAP2K4 mut | 8 | 2.02 | 0.06 | 0.986–4.19 | 0.40 |
| BRCA1 mut | 2 | 3.93 | 0.06 | 0.94–16.5 | 0.40 |
| RB1 loss | 4 | 2.62 | 0.06 | 0.95–7.25 | 0.40 |
| MDM2 amp | 6 | 2.19 | 0.06 | 0.95–5.05 | 0.40 |
| CREBBP mut | 3 | 2.86 | 0.08 | 0.90–9.13 | 0.43 |
| FAT1 mut/loss | 2 | 0.30 | 0.09 | 0.07–1.22 | 0.52 |
| FRS2 amp | 3 | 2.66 | 0.10 | 0.83–8.53 | 0.48 |
| ATRX mut | 2 | 3.17 | 0.11 | 0.77–13.05 | 0.50 |
| PTEN loss | 22 | 1.45 | 0.12 | 0.90–2.33 | 0.52 |
| ERBB2 mut | 8 | 1.76 | 0.13 | 0.85–3.68 | 0.52 |
Mut, mutation; amp, amplification.